Subsequently, there is significant interest in utilizing antibodies directed toward PHF-1 (an antibody that targets pS396/S404-tau) as immunotherapies for AD (Asuni et al., 2007; Bi et al., 2011; Chukwu et al., 2018). This evidence concerns the gene PHF1 and Alzheimer disease.